The vaccine, developed by the University of Oxford in collaboration with its commercial partner AstraZeneca, produces immunity against the coronavirus in all age groups, says AstraZeneca.
The Oxford vaccine has progressed to so-called phase III tests involving tens of thousands of people around the world.
Officially, the test results have not yet been published. The results have been submitted to a scientific journal and are subject to peer review according to scientific practice.
In a closed academic meeting, AstraZeneca has presented preliminary results to researchers.
People over 56 years of age and in some cases over 70 years of age developed the vaccine after receiving similar resistance as young volunteers in the test.
Protecting older people is a key issue in the development of vaccines. The body’s natural resistance decreases with age. Vaccines may also be less effective in the elderly.
“It is encouraging that the immune response was similar in older people and young adults,” said an AstraZeneca spokesman. The Guardianin by.
Long-term protection is a complete mystery
Several researchers believe that the first vaccines to be authorized and introduced will not provide full protection against COVID-19.
They may reduce the severity of the disease and reduce the need for hospitalization of sufferers and also reduce deaths.
It is impossible to get valid results from the long-term effectiveness of vaccines until years later.